Sulfated galactan derivatives from <em>Gracilaria fisheri</em> suppress the proliferation of MCF‑7 breast cancer cells by inducing cell cycle arrest

Phanphak,Jenjiralai; Somintara,Somsuda; Sakaew,Waraporn; Senarai,Thanyaporn; Kovensky,José; Wongprasert,Kanokpan; Rudtanatip,Tawut

doi:10.3892/wasj.2025.365

Sulfated galactan derivatives from Gracilaria fisheri suppress the proliferation of MCF‑7 breast cancer cells by inducing cell cycle arrest

Authors:
- Jenjiralai Phanphak
- Somsuda Somintara
- Waraporn Sakaew
- Thanyaporn Senarai
- José Kovensky
- Kanokpan Wongprasert
- Tawut Rudtanatip
View Affiliations

Affiliations: Electron Microscopy Unit, Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand, Laboratory of Glycochemistry and Agroresources UR 7378, Picardie Institute of Chemistry FR 3085, University of Picardie Jules Verne, 80000 Amiens, France, Department of Anatomy, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
Published online on: June 17, 2025 https://doi.org/10.3892/wasj.2025.365
Article Number: 77
Copyright : © Phanphak et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most prevalent diseases affecting the female population, with its incidence increasing globally. Previous studies have identified cyclins, CDKs and upstream signaling molecules as key therapeutic targets, as their overexpression can drive the transformation of normal cells into cancerous ones. Sulfated galactan (SG), a polysaccharide derived from Gracilaria fisheri, has demonstrated potential in modulating cellular functions. Recent research suggests that low molecular weight SG (LSG), when supplemented with an octanoyl ester (LSGO), exhibits an enhanced biological activity. However, the anticancer effects of SG and its derivatives in breast cancer remain underexplored. The present study thus aimed to examine the effects of SG, LSG and LSGO on MCF‑7 breast cancer cells. Cytotoxicity was initially assessed in L929 normal fibroblast cells and MCF‑7 cells. While all three forms were non‑toxic to L929 cells, LSGO exhibited slight cytotoxicity and significantly induced cell cycle arrest at the G2/M phase. Mechanistically, LSGO suppressed the PI3K/AKT/mTOR and ERK pathways, downregulated cyclins and CDKs, and led to cell cycle arrest and reduced cell proliferation. These results suggest that the structural modification of SG enhances its anti‑proliferative capacity, highlighting LSGO as a promising candidate for the treatment of MCF‑7 cells. Overall, these findings provide insight into the molecular mechanisms by which SG derivatives affect breast cancer cell proliferation and underscore their potential as anti‑proliferative agents targeting cell cycle regulatory proteins.

View Figures

View References

1	Ilango S, Paital B, Jayachandran P, Padma PR and Nirmaladevi R: Epigenetic alterations in cancer. Front Biosci (Landmark Ed). 25:1058–1109. 2020.PubMed/NCBI View Article : Google Scholar
2	Damiescu R, Efferth T and Dawood M: Dysregulation of different modes of programmed cell death by epigenetic modifications and their role in cancer. Cancer Lett. 584(216623)2024.PubMed/NCBI View Article : Google Scholar
3	Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, et al: Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 5:77–106. 2018.PubMed/NCBI View Article : Google Scholar
4	Lee S, Rauch J and Kolch W: Targeting MAPK signaling in cancer: Mechanisms of drug resistance and sensitivity. Int J Mol Sci. 21(1102)2020.PubMed/NCBI View Article : Google Scholar
5	Dong C, Wu J, Chen Y, Nie J and Chen C: Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 12(628690)2021.PubMed/NCBI View Article : Google Scholar
6	Mangé A, Coyaud E, Desmetz C, Laurent E, Béganton B, Coopman P, Raught B and Solassol J: FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer. Theranostics. 9:7003–7015. 2019.PubMed/NCBI View Article : Google Scholar
7	Palmer N and Kaldis P: Less-well known functions of cyclin/CDK complexes. Semin Cell Dev Biol. 107:54–62. 2020.PubMed/NCBI View Article : Google Scholar
8	Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J and Cui Q: The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 21(1960)2020.PubMed/NCBI View Article : Google Scholar
9	Al Bitar S and Gali-Muhtasib H: The role of the cyclin dependent kinase inhibitor p21^cip1/waf1 in targeting cancer: Molecular mechanisms and novel therapeutics. Cancers (Basel). 11(1475)2019.PubMed/NCBI View Article : Google Scholar
10	Menon SS, Guruvayoorappan C, Sakthivel KM and Rasmi RR: Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 491:39–45. 2019.PubMed/NCBI View Article : Google Scholar
11	Burcombe R, Wilson GD, Dowsett M, Khan I, Richman PI, Daley F, Detre S and Makris A: Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Res. 8(R31)2006.PubMed/NCBI View Article : Google Scholar
12	Liyanage UE, Law MH, Han X, An J, Ong JS, Gharahkhani P, Gordon S, Neale RE and Olsen CM: 23andMe Research Team et al. Combined analysis of keratinocyte cancers identifies novel genome-wide loci. Hum Mol Genet. 28:3148–3160. 2019.PubMed/NCBI View Article : Google Scholar
13	Sae-Lao T, Tohtong R, Bates DO and Wongprasert K: Sulfated galactans from red seaweed Gracilaria fisheri target EGFR and inhibit cholangiocarcinoma cell proliferation. Am J Chin Med. 45:615–633. 2017.PubMed/NCBI View Article : Google Scholar
14	Sae-Lao T, Luplertlop N, Janvilisri T, Tohtong R, Bates DO and Wongprasert K: Sulfated galactans from the red seaweed Gracilaria fisheri exerts anti-migration effect on cholangiocarcinoma cells. Phytomedicine. 36:59–67. 2017.PubMed/NCBI View Article : Google Scholar
15	Fan J, Zhu J, Zhu H, Zhang Y and Xu H: Potential therapeutic target for polysaccharide inhibition of colon cancer progression. Front Med (Lausanne). 10(1325491)2024.PubMed/NCBI View Article : Google Scholar
16	Rudtanatip T, Somintara S, Sakaew W, El-Abid J, Cano ME, Jongsomchai K, Wongprasert K and Kovensky J: Sulfated galactans from Gracilaria fisheri with supplementation of octanoyl promote wound healing activity in vitro and in vivo. Macromol Biosci. 22(e2200172)2022.PubMed/NCBI View Article : Google Scholar
17	Srimongkol P, Songserm P, Kuptawach K, Puthong S, Sangtanoo P, Thitiprasert S, Thongchul N, Phunpruch S and Karnchanatat A: Sulfated polysaccharides derived from marine microalgae, Synechococcus sp. VDW, inhibit the human colon cancer cell line Caco-2 by promoting cell apoptosis via the JNK and p38 MAPK signaling pathway. Algal Res. 69(102919)2023.
18	Aslama A, Bergerb MR, Ullaha I, Hameeda A and Masoodc F: Preparation and evaluation of cytotoxic potential of paclitaxel containing poly-3-hydroxybutyrate-co-3-hydroxyvalarate (PTX/PHBV) nanoparticles. Braz J Biol. 83(e275688)2023.PubMed/NCBI View Article : Google Scholar
19	Dehghani N, Tafvizi F and Jafari P: Cell cycle arrest and anti-cancer potential of probiotic Lactobacillus rhamnosus against HT-29 cancer cells. Bioimpacts. 11:245–252. 2021.PubMed/NCBI View Article : Google Scholar
20	Intuyod K, Hahnvajanawong C, Pinlaor P and Pinlaor S: Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro. Anticancer Res. 39:4837–4843. 2019.PubMed/NCBI View Article : Google Scholar
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
22	Shendge AK, Basu T and Mandal N: Evaluation of anticancer activity of Clerodendrum viscosum leaves against breast carcinoma. Indian J Pharmacol. 53:377–383. 2021.PubMed/NCBI View Article : Google Scholar
23	Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.PubMed/NCBI View Article : Google Scholar
24	Marquette C and Nabell L: Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol. 13:263–275. 2012.PubMed/NCBI View Article : Google Scholar
25	He X, Xue M, Jiang S, Li W, Yu J and Xiang S: Fucoidan promotes apoptosis and inhibits EMT of breast cancer cells. Biol Phram Bull. 42:442–447. 2019.PubMed/NCBI View Article : Google Scholar
26	Chantree P, Na-Bangchang K and Martviset P: Anticancer activity of fucoidan via apoptosis and cell cycle arrest on cholangiocarcinoma cell. Asian Pac J Cancer Prev. 22:209–217. 2021.PubMed/NCBI View Article : Google Scholar
27	Wongprasert K, Rudtanatip T and Praiboon J: Immunostimulatory activity of sulfated galactans isolated from the red seaweed Gracilaria fisheri and development of resistance against white spot syndrome virus (WSSV) in shrimp. Fish Shellfish Immunol. 36:52–60. 2014.PubMed/NCBI View Article : Google Scholar
28	Li N, Wang C, Georgiev MI, Bajpai VK, Tundis R, Simal-Gandara J, Lu X, Xiao J, Tang X and Qiao X: Advances in dietary polysaccharides as anticancer agents: Structure-activity relationship. Trends Food Sci Technol. 111:360–377. 2021.
29	Lu J, Shi KK, Chen S, Wang J, Hassouna A, White LN, Merien F, Xie M, Kong Q, Li J, et al: Fucoidan extracted from the New Zealand Undaria pinnatifida-physicochemical comparison against five other fucoidans: Unique low molecular weight fraction bioactivity in breast cancer cell lines. Mar Drugs. 16(461)2018.PubMed/NCBI View Article : Google Scholar
30	Wang Y, Xing M, Cao Q, Ji A, Liang H and Song S: Biological activities of fucoidan and the factors mediating its therapeutic effects: A review of recent studies. Mar Drugs. 17(183)2019.PubMed/NCBI View Article : Google Scholar
31	Sakaew W, Somintara S, Jongsomchai K, El Abid J, Wongprasert K, Kovensky J and Rudtanatip T: Octanoyl esterification of low molecular weight sulfated galactan enhances the cellular uptake and collagen expression in fibroblast cells. Biomed Rep. 19(99)2023.PubMed/NCBI View Article : Google Scholar
32	Davey MG, Hynes SO, Kerin MJ, Miller N and Lowery AJ: Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 13(4455)2021.PubMed/NCBI View Article : Google Scholar
33	Yang C, Zhang J, Ding M, Xu K, Li L, Mao L and Zheng J: Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 20:570–575. 2018.PubMed/NCBI View Article : Google Scholar
34	Li LT, Jiang G, Chen Q and Zheng JN: Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 11:1566–1572. 2015.PubMed/NCBI View Article : Google Scholar
35	Ma L, Xu GB, Tang X, Zhang C, Zhao W, Wang J and Chen H: Anti-cancer potential of polysaccharide extracted from hawthorn (Crataegus.) on human colon cancer cell line HCT116 via cell cycle arrest and apoptosis. J Funct Foods. 64(103677)2020.
36	Abdala-Díaz RT, Casas-Arrojo V, Castro-Varela P, Riquelme C, Carrillo P, Medina MA, Cárdenas C, Becerra J and Pérez Manríquez C: Immunomodulatory, antioxidant, and potential anticancer activity of the polysaccharides of the fungus Fomitiporia chilensis. Molecules. 29(3628)2024.PubMed/NCBI View Article : Google Scholar
37	Akhtar MJ, Ahamed M, Alhadlaq HA, Alrokayan SA and Kumar S: Targeted anticancer therapy: Overexpressed receptors and nanotechnology. Clin Chim Acta. 436:78–92. 2014.PubMed/NCBI View Article : Google Scholar
38	Cheng JJ, Chang CC, Chao CH and Lu MK: Characterization of fungal sulfated polysaccharides and their synergistic anticancer effects with doxorubicin. Carbohydr Polym. 90:134–139. 2012.PubMed/NCBI View Article : Google Scholar
39	Asghar U, Witkiewicz AK, Turner NC and Knudsen ES: The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.PubMed/NCBI View Article : Google Scholar
40	Finn RS, Aleshin A and Slamon DJ: Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 18(17)2016.PubMed/NCBI View Article : Google Scholar
41	Gopinathan L, Tan SL, Padmakumar VC, Coppola V, Tessarollo L and Kaldis P: Loss of Cdk2 and cyclin A2 impairs cell proliferation and tumorigenesis. Cancer Res. 74:3870–3879. 2014.PubMed/NCBI View Article : Google Scholar
42	Jen CI, Lu MK, Lai MN and Ng LT: Sulfated polysaccharides of Laetiporus sulphureus fruiting bodies exhibit anti-breast cancer activity through cell cycle arrest, apoptosis induction, and inhibiting cell migration. J Ethnopharmacol. 321(117546)2024.PubMed/NCBI View Article : Google Scholar
43	Chen PH, Chiang PC, Lo WC, Su CW, Wu CY, Chan CH, Wu YC, Cheng HC, Deng WP, Lin HK and Peng BY: A novel fucoidan complex-based functional beverage attenuates oral cancer through inducing apoptosis, G2/M cell cycle arrest and retarding cell migration/invasion. J Funct Foods. 85(104665)2021.